Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

123 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prognostic value of health-related quality of life for overall survival in elderly non-small-cell lung cancer patients.
Fiteni F, Vernerey D, Bonnetain F, Vaylet F, Sennélart H, Trédaniel J, Moro-Sibilot D, Herman D, Laizé H, Masson P, Derollez M, Clément-Duchêne C, Milleron B, Morin F, Zalcman G, Quoix E, Westeel V. Fiteni F, et al. Among authors: vaylet f. Eur J Cancer. 2016 Jan;52:120-8. doi: 10.1016/j.ejca.2015.10.004. Epub 2015 Dec 10. Eur J Cancer. 2016. PMID: 26682871 Clinical Trial.
Second-line therapy in elderly patients with advanced nonsmall cell lung cancer.
Quoix E, Westeel V, Moreau L, Pichon E, Lavolé A, Dauba J, Debieuvre D, Souquet PJ, Bigay-Game L, Dansin E, Poudenx M, Molinier O, Vaylet F, Moro-Sibilot D, Herman D, Sennelart H, Tredaniel J, Mennecier B, Morin F, Baudrin L, Milleron B, Zalcman G; Intergroupe Francophone de Cancérologie Thoracique. Quoix E, et al. Among authors: vaylet f. Eur Respir J. 2014 Jan;43(1):240-9. doi: 10.1183/09031936.00048213. Epub 2013 Oct 10. Eur Respir J. 2014. PMID: 24114964 Free article.
Similar survival rates with first-line gefitinib, gemcitabine, or docetaxel in a randomized phase II trial in elderly patients with advanced non-small cell lung cancer and a poor performance status (IFCT-0301).
Des Guetz G, Landre T, Westeel V, Milleron B, Vaylet F, Urban T, Barlesi F, Souquet PJ, Debieuvre D, Braun D, Fraboulet G, Monnet I, Uzzan B, Molinier O, Morin F, Moro-Sibilot D, Morère JF. Des Guetz G, et al. Among authors: vaylet f. J Geriatr Oncol. 2015 May;6(3):233-40. doi: 10.1016/j.jgo.2015.02.002. Epub 2015 Feb 16. J Geriatr Oncol. 2015. PMID: 25698450 Clinical Trial.
Randomized phase II trial of gefitinib or gemcitabine or docetaxel chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2 or 3 (IFCT-0301 study).
Morère JF, Bréchot JM, Westeel V, Gounant V, Lebeau B, Vaylet F, Barlési F, Urban T, Souquet PJ, Debieuvre D, Baudrin L, Zalcman G, Morin F, Milleron B, Moro-Sibilot D. Morère JF, et al. Among authors: vaylet f. Lung Cancer. 2010 Dec;70(3):301-7. doi: 10.1016/j.lungcan.2010.03.003. Epub 2010 Apr 18. Lung Cancer. 2010. PMID: 20400201 Clinical Trial.
Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial.
Quoix E, Zalcman G, Oster JP, Westeel V, Pichon E, Lavolé A, Dauba J, Debieuvre D, Souquet PJ, Bigay-Game L, Dansin E, Poudenx M, Molinier O, Vaylet F, Moro-Sibilot D, Herman D, Bennouna J, Tredaniel J, Ducoloné A, Lebitasy MP, Baudrin L, Laporte S, Milleron B; Intergroupe Francophone de Cancérologie Thoracique. Quoix E, et al. Among authors: vaylet f. Lancet. 2011 Sep 17;378(9796):1079-88. doi: 10.1016/S0140-6736(11)60780-0. Epub 2011 Aug 8. Lancet. 2011. PMID: 21831418 Clinical Trial.
[A phase II study of cetuximab, pemetrexed, cisplatin, and concurrent radiotherapy in patients with locally advanced, unresectable, stage III, non squamous, non-small cell lung cancer (NSCLC)].
Tredaniel J, Mornex F, Barillot I, Diaz O, Hennequin C, Le Pechoux C, Lavole A, Giraud P, Souquet PJ, Teixeira L, Vaylet F, Zalcman G, Baudrin L, Morin F, Milleron B. Tredaniel J, et al. Among authors: vaylet f. Rev Mal Respir. 2011 Jan;28(1):51-7. doi: 10.1016/j.rmr.2010.06.027. Epub 2011 Jan 11. Rev Mal Respir. 2011. PMID: 21277474 Clinical Trial. French.
Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program.
Leduc C, Merlio JP, Besse B, Blons H, Debieuvre D, Bringuier PP, Monnet I, Rouquette I, Fraboulet-Moreau S, Lemoine A, Pouessel D, Mosser J, Vaylet F, Langlais A, Missy P, Morin F, Moro-Sibilot D, Cadranel J, Barlesi F, Beau-Faller M; French Cooperative Thoracic Intergroup (IFCT). Leduc C, et al. Among authors: vaylet f. Ann Oncol. 2017 Nov 1;28(11):2715-2724. doi: 10.1093/annonc/mdx404. Ann Oncol. 2017. PMID: 28945865 Free article.
Summary report of the Standards, Options and Recommendations for the management of patients with non-small-cell lung carcinoma (2000).
Depierre A, Lagrange JL, Theobald S, Astoul P, Baldeyrou P, Bardet E, Bazelly B, Bréchot JM, Breton JL, Douillard JY, Grivaux M, Jacoulet P, Khalil A, Lemarié E, Martinet Y, Massard G, Milleron B, Molina T, Moro-Sibilot D, Paesmans M, Pujol JL, Quoix E, Ranfaing E, Rivière A, Sancho-Garnier H, Souquet PJ, Spaeth D, Stoebner-Delbarre A, Thiberville L, Touboul E, Vaylet F, Vergnon JM, Westeel V; FNCLCC. Depierre A, et al. Among authors: vaylet f. Br J Cancer. 2003 Aug;89 Suppl 1(Suppl 1):S35-49. doi: 10.1038/sj.bjc.6601083. Br J Cancer. 2003. PMID: 12915902 Free PMC article. No abstract available.
Randomised, multicentre phase II study assessing two doses of docetaxel (75 or 100 mg/m2) as second-line monotherapy for non-small-cell lung cancer.
Quoix E, Lebeau B, Depierre A, Ducolone A, Moro-Sibilot D, Milleron B, Breton JL, Lemarie E, Pujol JL, Brechot JM, Zalcman G, Debieuvre D, Vaylet F, Vergnenegre A, Clouet P. Quoix E, et al. Among authors: vaylet f. Ann Oncol. 2004 Jan;15(1):38-44. doi: 10.1093/annonc/mdh005. Ann Oncol. 2004. PMID: 14679117 Free article. Clinical Trial.
123 results